MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
870.00
0.00 (0.00%)
At close: Apr 29, 2026
-32.08%
Market Cap 36.69B
Revenue (ttm) 11.22B
Net Income (ttm) -13.05B
Shares Out 42.17M
EPS (ttm) -340.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 144,879
Average Volume 406,801
Open 895.00
Previous Close 870.00
Day's Range 821.00 - 895.00
52-Week Range 577.00 - 2,250.00
Beta 0.67
RSI 41.25
Earnings Date May 15, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

In 2025, MOA Life Plus's revenue was 11.22 billion, a decrease of -28.24% compared to the previous year's 15.63 billion. Losses were -13.05 billion, 88.6% more than in 2024.

Financial Statements

News

There is no news available yet.